WO2002090382A3 - Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications - Google Patents

Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications Download PDF

Info

Publication number
WO2002090382A3
WO2002090382A3 PCT/FR2002/001533 FR0201533W WO02090382A3 WO 2002090382 A3 WO2002090382 A3 WO 2002090382A3 FR 0201533 W FR0201533 W FR 0201533W WO 02090382 A3 WO02090382 A3 WO 02090382A3
Authority
WO
WIPO (PCT)
Prior art keywords
mixture
peptides derived
papillomavirus
proteins
hpv
Prior art date
Application number
PCT/FR2002/001533
Other languages
English (en)
Other versions
WO2002090382A2 (fr
Inventor
Bernard Maillere
Isabelle Bourgault-Villada
Sandra Pouvelle-Moratille
Jean-Gerard Guillet
Original Assignee
Commissariat Energie Atomique
Inst Nat Sante Rech Med
Bernard Maillere
Isabelle Bourgault-Villada
Sandra Pouvelle-Moratille
Jean-Gerard Guillet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat Energie Atomique, Inst Nat Sante Rech Med, Bernard Maillere, Isabelle Bourgault-Villada, Sandra Pouvelle-Moratille, Jean-Gerard Guillet filed Critical Commissariat Energie Atomique
Priority to US10/476,570 priority Critical patent/US7488791B2/en
Priority to JP2002587459A priority patent/JP2005505503A/ja
Priority to EP02730391A priority patent/EP1383535A2/fr
Priority to CA 2446062 priority patent/CA2446062A1/fr
Priority to AU2002302713A priority patent/AU2002302713A1/en
Publication of WO2002090382A2 publication Critical patent/WO2002090382A2/fr
Publication of WO2002090382A3 publication Critical patent/WO2002090382A3/fr
Priority to US12/347,471 priority patent/US20100203080A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)

Abstract

Mélange de peptides issus des protéines E6 et/ou E7 d'un papillomavirus impliqué dans le cancer du col de l'utérus, tel que HPV16, HPV18, HPV30, HPV31, HPV32, HPV33, HPV34, HPV35, HPV39, HPV40, HPV42, HPV43, HPV44, HPV45, HPV51, HPV52, HPV56, HPV57 et HPV58, par exemple ainsi que ses applications en tant que médicament (dans des compositions immunogènes, aptes à stimuler la production de lymphocytes T CD4+ anti-HPV in vivo et donc utiles pour la vaccination contre les cancers du col de l'utérus et dans d'autres cancers) ou en tant que réactif de diagnostic de lymphocytes T spécifiques d'un HPV, notamment pour évaluer l'état immunitaire des patients. Mélange de peptides issus des protéines E6 et/ou E7 d'un papillomavirus impliqué dans des lésions bénignes de la peau (verrues par exemple), tel que HPV10, HPV3 ou HPV4 et ses applications en tant que médicament.
PCT/FR2002/001533 2001-05-04 2002-05-03 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications WO2002090382A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10/476,570 US7488791B2 (en) 2001-05-04 2002-05-03 Mixture of peptides derived from E6 and/or E7 papillomavirus proteins and uses thereof
JP2002587459A JP2005505503A (ja) 2001-05-04 2002-05-03 Ｅ６及び／又はｅ７パピローマウイルスタンパク質に由来するペプチドの混合物並びにその使用
EP02730391A EP1383535A2 (fr) 2001-05-04 2002-05-03 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
CA 2446062 CA2446062A1 (fr) 2001-05-04 2002-05-03 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
AU2002302713A AU2002302713A1 (en) 2001-05-04 2002-05-03 Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof
US12/347,471 US20100203080A1 (en) 2001-05-04 2008-12-31 Mixture of Peptides Derived from E6 and/or E7 Papillomavirus Proteins and Uses Thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR01/05980 2001-05-04
FR0105980A FR2824326B1 (fr) 2001-05-04 2001-05-04 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/347,471 Division US20100203080A1 (en) 2001-05-04 2008-12-31 Mixture of Peptides Derived from E6 and/or E7 Papillomavirus Proteins and Uses Thereof

Publications (2)

Publication Number Publication Date
WO2002090382A2 WO2002090382A2 (fr) 2002-11-14
WO2002090382A3 true WO2002090382A3 (fr) 2003-10-02

Family

ID=8862980

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/001533 WO2002090382A2 (fr) 2001-05-04 2002-05-03 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications

Country Status (7)

Country Link
US (2) US7488791B2 (fr)
EP (1) EP1383535A2 (fr)
JP (1) JP2005505503A (fr)
AU (1) AU2002302713A1 (fr)
CA (1) CA2446062A1 (fr)
FR (1) FR2824326B1 (fr)
WO (1) WO2002090382A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
DE10336916B4 (de) * 2003-08-07 2015-02-19 Danfoss A/S Regelventil und Wärmetauscheranordnung
WO2006037059A2 (fr) * 2004-09-27 2006-04-06 The Johns Hopkins Universtiy Systeme de spectrometrie de masse de point d'intervention
JP2008044848A (ja) * 2004-11-30 2008-02-28 Univ Kurume Ｈｌａ−ａ２４拘束性腫瘍抗原ペプチド
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
ES2310072B1 (es) * 2005-12-23 2009-11-16 Proyecto De Biomedicina Cima, S.L. Nuevos peptidos determinantes antigenicos t colaboradores (/dth).
US8859218B2 (en) * 2008-06-13 2014-10-14 Oncohealth Corp. In situ detection of early stages and late stages HPV infection
US8916342B2 (en) 2006-11-13 2014-12-23 Oncohealth Corp. Identification of high grade or ≧ CIN2 for early stages and late stages detection, screening, and diagnosis of human papillomavirus (HPV) and HPV-associated cancers
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
JP6035503B2 (ja) 2007-05-31 2016-11-30 アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク ワクチンで使用するための、子宮頸部悪性腫瘍に浸潤するｔ細胞によって標的とされるｈｐｖエピトープ
AU2013205259B2 (en) * 2007-05-31 2015-06-11 Isa Pharmaceuticals B.V. HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
KR20090103571A (ko) * 2008-03-28 2009-10-01 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
CA2721366C (fr) 2008-04-17 2017-06-06 Elizabeth Ann Vasievich Stimulation de reponse immunitaire par des enantiomeres de lipides cationiques
AR074485A1 (es) * 2009-12-04 2011-01-19 Consejo Nac Invest Cient Tec Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos
EP2521914A4 (fr) 2010-01-08 2013-07-10 Oncohealth Corp Immunoessais sur le vph à base de cellule et à haut débit pour diagnostiquer et dépister des cancers associés au vph
CN102060929A (zh) * 2010-06-07 2011-05-18 夏书奇 T细胞免疫平衡肽
WO2012072088A1 (fr) 2010-12-02 2012-06-07 Bionor Immuno As Conception d'échafaudage peptidique
AU2013317805B2 (en) 2012-09-21 2018-07-26 Pds Biotechnology Corporation Improved vaccine compositions and methods of use
FR3008099B1 (fr) 2013-07-05 2020-08-07 Commissariat Energie Atomique Peptides immunogenes de l'antigene tumoral cycline b1
EP3058956A1 (fr) 2015-02-23 2016-08-24 Institut Curie Vaccination/radiothérapie combinée pour le traitement du cancer
EP3374496A4 (fr) 2015-11-13 2019-07-10 PDS Biotechnology Corporation Lipides en tant que vecteurs synthétiques pour améliorer le traitement et la présentation de l'antigène ex-vivo en thérapie cellulaire dendritique
US10702598B2 (en) 2016-06-20 2020-07-07 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine
EP3267119A1 (fr) 2016-07-07 2018-01-10 E.ON Sverige AB Système de chauffage et de refroidissement combiné
MX2019003961A (es) * 2016-10-05 2019-08-26 Pds Biotechnology Corp Vacunas novedosas del vph16 con celulas t no restringidas por hla, composiciones y metodos de uso de las mismas.
CA3088837A1 (fr) * 2018-01-24 2019-08-01 The Council Of The Queensland Institute Of Medical Research Immunotherapie de l'hpv
WO2019210055A2 (fr) * 2018-04-26 2019-10-31 Agenus Inc. Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
WO2020112720A1 (fr) * 2018-11-28 2020-06-04 The General Hospital Corporation Vaccins anticancéreux dirigés contre les lymphocytes t contre des virus commensaux
EP4281106A1 (fr) * 2021-01-21 2023-11-29 The General Hospital Corporation Vaccins anticancéreux ciblant des lymphocytes t contre des virus commensaux pour le traitement de carcinomes muqueux

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075336A2 (fr) * 1999-06-03 2000-12-14 Biovector Therapeutics Fragment proteiques polyepitopiques des proteines e6 et e7 de hpv, leur obtention et leurs utilisations notamment en vaccination

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
US5932412A (en) * 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
EP0523391B1 (fr) * 1991-07-13 2003-03-19 Dade Behring Marburg GmbH Utilisation des peptides dérivés des E6 et E7 gènes de HPV-16 pour l'usage diagnostique
RS50101B (sr) * 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
WO1999034826A1 (fr) * 1998-01-09 1999-07-15 Circassia Limited Procedes et compositions de desensibilisation
CA2377525A1 (fr) * 1999-07-19 2001-03-29 Epimmune, Inc. Induction de reponses immunitaires cellulaires au virus de l'hepatite c mettant en oeuvre des compositions de peptides et d'acide nucleique
SE9903031D0 (sv) * 1999-08-27 1999-08-27 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
DE60042556D1 (de) * 1999-09-16 2011-02-10 Eisai Inc Für polyepitop-polypeptide kodierende nukleinsäuren
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
JP4873810B2 (ja) * 1999-10-05 2012-02-08 エピミューン インコーポレイテッド ペプチドおよび核酸組成物を使用する、ヒト免疫不全ウイルス−１に対する細胞性免疫応答の誘導

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075336A2 (fr) * 1999-06-03 2000-12-14 Biovector Therapeutics Fragment proteiques polyepitopiques des proteines e6 et e7 de hpv, leur obtention et leurs utilisations notamment en vaccination

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOURGAULT-VILLADA I. ET AL.: "Identification in humans of HPC-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif.", EUR. J. IMMUNOL., vol. 30, 2000, pages 2281 - 2289, XP002226985 *
RESSING ME ET AL: "Human CTL Epitopes Encoded by Human Papillomavirus Type 16 E6 and E7 Identified Through In Vivo and In Vitro Immunogenicity Studies of HLA-A*0201-Binding Peptides", JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO, US, vol. 154, 1995, pages 5934 - 5943, XP002209568, ISSN: 0022-1767 *
See also references of EP1383535A2 *

Also Published As

Publication number Publication date
AU2002302713A1 (en) 2002-11-18
FR2824326B1 (fr) 2004-03-19
EP1383535A2 (fr) 2004-01-28
US20040170644A1 (en) 2004-09-02
US20100203080A1 (en) 2010-08-12
JP2005505503A (ja) 2005-02-24
WO2002090382A2 (fr) 2002-11-14
CA2446062A1 (fr) 2002-11-14
FR2824326A1 (fr) 2002-11-08
US7488791B2 (en) 2009-02-10

Similar Documents

Publication Publication Date Title
WO2002090382A3 (fr) Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
Schellenbacher et al. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses
De Villiers Heterogeneity of the human papillomavirus group
JP5474567B2 (ja) パピローマウイルスワクチン
CA3167595A1 (fr) Epitopes du papillomavirus humain cibles par des lymphocytes t infiltrant des tumeurs cervicales malignes pour utilisation en tant que vaccins
Feoli‐Fonseca et al. Human papillomavirus (HPV) study of 691 pathological specimens from Quebec by PCR‐direct sequencing approach
Huber et al. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types
Gu et al. Genotype distribution characteristics of high-risk human papillomaviruses in women from Shanghai, China
Olczak et al. RG2-VLP: a vaccine designed to broadly protect against anogenital and skin human papillomaviruses causing human cancer
Matoso et al. Prevalence and distribution of 15 high-risk human papillomavirus types in squamous cell carcinoma of the scrotum
Webb et al. Cervical cancer-causing human papillomaviruses have an alternative initiation site for the L1 protein
St. Georgieva et al. Nature of cervical cancer and other HPV-associated cancers.
Mandic Primary prevention of cervical cancer: prophylactic human papillomavirus vaccines
Sanchez et al. Detection of variable genotypes in common human papillomavirus-associated invasive penile squamous cell carcinomas: a study of 177 human papillomavirus-positive cases
CN114716560B (zh) 一种人乳头瘤病毒18型嵌合蛋白及其用途
JP2013540421A5 (fr)
Bowden et al. Human papillomavirus
RU2013106498A (ru) Антигенные композиции папилломавируса человека е7 и их применение
Grce et al. Burden and prevention of HPV related diseases: Situation in Croatia
Buttà et al. Concurrence and concordance of Human Papillomavirus in orogenital infection
Dimčić et al. Digital squamous cell carcinoma associated with possibly carcinogenic human papillomavirus type 73 (HPV73): a case report
Simon et al. Cervical response to vaccination against HPV16 E7 in case of severe dysplasia
Hariharan et al. Genotypes of the human papillomavirus: Relevance to Indian field trials of the vaccine
Lacey Unresolved issues in the management of human papillomavirus-associated mucosal high-grade pre-cancers
張士泰 The prevalence of VAIN, CIN, and related HPV genotypes in Japanese women with abnormal cytology

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002587459

Country of ref document: JP

Ref document number: 2446062

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002730391

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002730391

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10476570

Country of ref document: US